Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANDFLY Study
PACTR202606512729198Phase 1Not yet recruiting
- Sponsor
- Gennova Biopharmaceuticals Ltd.
- Start
- Aug 2026
- Countries
- 1
01
Overview
Phase 1 trial in leishmaniasis (2 arms), sponsored by Gennova Biopharmaceuticals Ltd. Primary endpoints: Frequency and severity of vaccine-related events and Frequency of serious adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
leishmaniasis
Beyond the preview
Go deeper on PACTR202606512729198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606512729198.